DOE Review Summary & Next Steps

Steve Holmes
PIP-II Technical Meeting
22 November 2016
Closeout

- Closeout Slides are available on the review indico site: [https://indico.fnal.gov/conferenceDisplay.py?confId=13019](https://indico.fnal.gov/conferenceDisplay.py?confId=13019)

- Message:
  Technical development is ahead of pace, project development is behind pace, for CD-1.
  → To receive CD-1 a year from now will required adjustment of the balance between R&D and project development.

- Everything else is just details…
Closeout

• A few of the interesting details:
  – Consider and reach agreement with DOE on the alignment of R&D goals with the various CD’s (2, 3a, 3)
  – Develop the Risk Register asap – need this to talk to DOE
  – Need a physics requirements document
  – Need an MOU with the laboratory
  – Both supported by an assumptions document
Next Steps*

We will be developing a plan over the next several weeks. This may involve moving some people reassignments as we have limited ability to bring new people on board:

- **Conceptual Design Report**
  - Complete by March 1 – for P2MAC review in April

- **Resource Loaded Schedule**
  - R&D at detailed level
  - Construction to rely significantly on planning packages

- **Cost Estimate**
  - BOEs
  - Benchmarking
  - Contingency

* Note: No significant R&D is required for CD-1; however, in adjusting balance we need to keep in mind goals for CD-2 and beyond
Next Steps

• Assumptions Document
  – Cost
    • Int’l contributions
    • Operations vs construction
    • Lab overheads – overhead functions direct support vs overhead
  – Schedule
    • Funding profile
    • LBNF ( Shutdowns )
  – Interfaces
    • LBNF
    • Int’l collaborators
    • Accelerator Complex
Next Steps (cont)

• Project FRS
• Risk Registry
  – Technical, Cost, Schedule
  – Mitigation strategy
  – Associated contingency
• CD alignment with R&D
  – Derived from Risk Register and Assumptions
• Lab MOU
  – Derived from Assumptions document
• Everything Else
Process

- Everything ready
  ITR (April P2MAC)
  ICR
  Director’s Review
  DOE Review
  ESAAB
- CD-1

Note: The view of the committee was that best-case scenario is CD-1 a year from now.